# A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

> **NCT03018067** · PHASE2 · TERMINATED · sponsor: **Ardelyx** · enrollment: 60 (estimated)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** RDX227675
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03018067
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Sponsor stopped program\]
- **Last updated:** 2019-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03018067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03018067, "A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03018067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*